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Background: Current urine-based assays for bladder cancer (BCa) diagnosis lack accuracy, so the search for
improved biomarkers continues. Through genomic and proteomic profiling of urine, we have identified a panel of
biomarkers associated with the presence of BCa. In this study, we evaluated the utility of three of these biomarkers,
interleukin 8 (IL-8), Matrix metallopeptidase 9 (MMP-9) and Syndecan in the diagnosis of BCa through urinalysis.
Methods: Voided urines from 127 subjects, cancer subjects (n = 64), non-cancer subjects (n = 63) were analyzed. The
protein concentrations of IL-8, MMP-9, and Syndecan were assessed by enzyme-linked immunosorbent assay
(ELISA). Data were also compared to a commercial ELISA-based BCa detection assay (BTA-Trak©) and urinary
cytology. We used the area under the curve of a receiver operating characteristic (AUROC) to compare the
performance of each biomarker.
Results: Urinary protein concentrations of IL-8, MMP-9 and BTA were significantly elevated in BCa subjects. Of the
experimental markers compared to BTA-Trak©, IL-8 was the most prominent marker (AUC; 0.79; 95% confidence
interval [CI], 0.72-0.86). Multivariate regression analysis revealed that only IL-8 (OR; 1.51; 95% CI, 1.16-1.97, p= 0.002)
was an independent factor for the detection of BCa.
Conclusions: These results suggest that the measurement of IL-8 in voided urinary samples may have utility for
urine-based detection of BCa. These findings need to be confirmed in a larger, prospective cohort.
Keywords: IL-8, Biomarkers, Diagnosis, Bladder cancerBackground
Voided urinary cytology (VUC) remains the most estab-
lished adjunct to cystoscopy in the detection of BCa.
While VUC has a specificity of >93%, its sensitivity is
only 25-40%, especially for low-grade and low-stage
tumors [1]. Commercial tests measuring nuclear matrix
protein (NMP-22) and bladder tumor antigen (BTA)
have emerged as diagnostic urinary protein assays for
BCa. The analysis of naturally shed urothelial cells
isolated from the urine, as used in VUC, can be
enhanced by combining VUC with molecular assays to
detect protein biomarkers or aberrant chromosomes.
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reproduction in any medium, provided the ordetect mucin antigen and carcinoembryonic antigen on
urothelial cells [2]. Urovysion©, a fluorescence in situ
hybridization assay designed to detect aneuploidy for
chromosomes 3, 7, 17, and loss of the 9p21, can be
applied to VUC slides [3]. Unlike VUC, these tests have
a lower specificity, thus there is currently no urine test
for BCa that dominates the field.
The inadequate power of a single biomarker may partly
explain why detecting BCa using urinalysis remains a
challenge. There needs to be an evolution towards tests
that monitor multiple biomarkers in order to achieve the
desired diagnostic accuracy. We have recently identified
diagnostic molecular signatures for BCa using a number
of discovery approaches. Utilizing genome-wide mRNA
profiling, we analyzed shed urothelia isolated from 92
voided urine samples. Microarray analysis identified the
expression of 52 genes as being significantly associated
with BCa. The expression of a selection of this genesetLtd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic, clinicopathologic characteristics
and concentration of urinary proteins in the study cohort
Non-cancer (%) Cancer (%)
N=63 N=64
Median Age (range, y) 60 (30-81) 69.5 (22-90)
Male : Female ratio 55 : 8 55 : 9
Race
White 41 (65) 58(91)
African American 8 (13) 0(0)
Other 14 (22) 6 (9)
Tobacco use 25 (40) 54 (84)
Gross hematuria 1 (2) 47 (73)
Suspicious/positive cytology 1 (2) 18 (28)




T1 n/a 9 (14)
T2 n/a 31(48)
T3 n/a 4 (6)
T4 n/a 2 (3)




Urinary Proteins Median (range) Median (range)
IL-8 (pg/ml) 0(0 - 134.33) 128.43 (0 - 17140.2)
MMP–9 (ng/ml) 0 (0 – 14.25) 0.95 (0 – 1002.6)
Syndecan (ng/ml) 40.67(0 - 199.55) 31.81 (0 - 335.18)
BTA-Trak (U/ml) 13.13(0.5 - 36.87) 179.33 (0 - 24865.4)
Hemoglobin (ng/ml) 0(0 - 125.92) 8.73 (0 - 130367.5)
Mean + SD Mean + SD
IL-8 (pg/ml) 05.02 ± 20.99 1335.07 ±3495.26
MMP–9 (ng/ml) 0.35 ±1.83 46.76 ±142.16
Syndecan (ng/ml) 49.10 ± 42.09 55.04 ± 74.88
BTA-Trak (U/ml) 14.66 ± 8.05 1630.5 ± 3954.5
Hemoglobin (ng/ml) 2.63±15.97 4451.3±22814.4
^, 4 subjects with concomitant cis had T1 (n=2) and T2 (n=2) disease.
~, Subjects with T2 (n=1), T3 (=1) and T4 (n=1) disease and node positive.
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independent cohort of 81 patients (manuscript submit-
ted). In a separate study, we utilized a dual-lectin affinity
chromatography and mass spectrometry platform to
analyze the supernatant of voided urine samples from
100 subjects (54 cancer subjects and 46 non-cancer
subjects). The analyses identified 265 distinct glycopro-
teins present in urine, and several that were significantly
associated with the presence of BCa. A panel of 9
glycoproteins was subsequently validated by protein
assay [4]. Next the above genomics and proteomics data
were integrated and analyzed by sophisticated bioinfor-
matics leading to a panel of candidate biomarkers. Our
ultimate aim is to validate the panel of candidate biomar-
kers in patients with newly diagnosed BCa. In this study,
we investigated the utility of three of the potential BCa
candidate biomarkers, interleukin 8 (IL-8), matrix
metallopeptidase 9 (MMP-9) and Syndecan, by measur-
ing the presence of these proteins in voided urine
samples obtained from an independent cohort of 127
subjects.
Methods
Specimen and data collection
Under Institutional Review Board approval and informed
consent (IRB #560-2006), voided urine samples, and
associated clinical information were prospectively col-
lected. The study cohort consisted of 63 individuals with
no previous history of urothelia carcinoma, gross
hematuria, active urinary tract infection or urolithiasis,
and 64 individuals with newly diagnosed primary urothe-
lia cell carcinoma. Median follow-up was 11.5 months.
This cohort of 127 subjects served as our phase II (valid-
ation study) according to the International Consensus
Panel on Bladder Tumor Markers [5] and was reported
based on the STARD criteria [6]. All subjects were evalu-
ated in the outpatient Urology clinic. Urinalysis, urinary
cytology and BTA-Trak© were performed on all subjects.
Furthermore, in our cancer group, axial imaging of the
abdomen and pelvis and cystoscopy were performed, and
urothelial cell carcinoma was confirmed by histological
examination of excised tissue. Pertinent information on
clinical presentation, staging and histologic grading [7,8]
and outcome were recorded (Table 1).
Specimen processing and analysis
Prior to any type of therapeutic intervention, 100 mL of
voided urine was obtained from each subject. Fifty
milliliters of urine was sent to the clinical laboratory for
urinalysis and urinary cytology. The remaining 50 ml of
urine was assigned a unique identifying number before
immediate delivery and laboratory processing. Each urine
sample was centrifuged at 600 × g 4°C for 5 min. The
supernatant was decanted and aliquoted, and the urinarypellet was snap frozen. Both the supernatant and pellet
were stored at -80 °C prior to analysis. Urine supernatant
protein concentration was determined using Pierce
660-nm Protein Assay Kit (Thermo Fisher Scientific Inc.,
Waltham, MA, USA).
Enzyme-linked Immunosorbent Assays for IL-8, MMP-9,
Syndecan, Hemoglobin and Bladder Tumor Antigen (BTA).
The levels of human IL-8 (Cat # ab46032 Abcam,
Cambridge, MA, USA), human MMP-9 (Cat# DMP900
R&D Systems Inc., Minneapolis, MN, USA) and human
Syndecan (Cat# ab46507 Abcam, Cambridge, MA, USA)
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immunosorbent assays. Commercially available ELISA
assays were used to measure levels of urinary
hemoglobin (Cat#E88-135 Bethyl Laboratories Inc.,
Montgomery, TX, USA) and BTA (BTA-Trak© Ca#
662150 Polymedco Inc. Cortlandt Manor, NY, USA). The
assays were conducted according to the manufacturer’s
instructions. Laboratory personnel were blinded to final
diagnosis. Calibration curves were prepared using puri-
fied standards for each protein assessed. Curve fitting
was accomplished by either linear or four-parameter
logistic regression following manufacturer’s instructions.
Protein concentration levels were normalized using
urinary creatinine concentrations.
Data analysis
The association between a biomarker and BCa was
tested using Wilcoxon rank sum test. Spearman rank
correlation coefficients were used to examine the correl-
ation between urinary tumor biomarker (IL-8, MMP-9,
Syndecan and BTA) concentrations and urinary
hemoglobin concentration. Nonparametric receiver oper-
ating characteristic (ROC) curves were generated in
which the value for sensitivity is plotted against false-
positive rate (1-specificity). Areas under ROC curves
were estimated and compared by chi-square test. We
defined a diagnostic test (positive vs. negative) for BCa
using a cutoff threshold for each biomarker. The optimal
cutoff (Youden index) was selected to maximize the
sum of the sensitivity and specificity [9]. The overall
accuracy of a biomarker to predict BCa is defined as the
average of the sensitivity and the specificity. To assess
the independent association between biomarkers, logistic
regression analysis with BCa status (yes vs. no) as the
dependent variable and IL-8, MMP-9, Syndecan, BTA
concentrations as explanatory variables. In multivariate
logistic analysis, the log-transformation was used to
reduce the skewness of each biomarker. Statistical
significance in this study was set at p< 0.05 and all
reported p values were 2-sided. All analyses were
performed with SAS software version 9. 3.
Results
The cohort of 127 subjects consisted of 64 subjects with
active BCa and 63 control subjects. Demographic, clin-
ical and pathologic characteristics of both groups are
illustrated in Table 1. In the cancer cohort, urinary
cytology only had a sensitivity of 28%. Median urinary
concentrations of IL-8 (128.43 pg/ml vs. 0 pg/ml,
p< 0.0001), MMP-9 (0.95 ng/ml vs. 0 ng/ml, p< 0.0001),
and BTA (179.34 U/ml vs. 13.13 U/ml, p< 0.0001) were
significantly higher in subjects with BCa compared to
subjects without BCa. Median urinary Syndecan concen-
tration in the cohort with BCa was similar to that in thecohort without BCa (31.81 ng/ml vs. 40.67 ng/ml,
p= 0.30). ELISA data are presented in a boxplot figure
(Figure 1).
The level of hematuria was assessed in all cases by
reviewing the clinical record for each subject, by analyz-
ing voided urine samples with Clinitek point of care
urinalysis testing©, and quantitatively by performing a
hemoglobin ELISA on all urine samples. The qualitative
analyses revealed that 83% of BCa subjects were noted to
have hemoglobin in their urine samples compared with
only 23% of control subjects. The median urinary levels
of hemoglobin in BCa subjects compared to control
subjects were 8.73 ng/ml vs. 0 ng/ml, p< 0.0001. Inter-
estingly, of the four biomarkers assessed, BTA had the
highest correlation coefficient to urinary hemoglobin
(0.732).
The ability of the above biomarkers to predict the
presence of BCa was analyzed using nonparametric ROC
analyses and the area under the ROC curve (AUROC),
according to National Cancer Institute guidelines [10].
We determined the Youden Index cutoff values to
maximize the sum of sensitivity and specificity. BTA
served as our positive control and was noted to have an
AUROC of 0.75 (95% CI: 0.66-0.85, Figure 2). Using the
Youden Index cutoff value (Figure 2), urinary BTA pro-
vided a sensitivity of 64%, specificity of 100%, positive
predictive value of 100%, negative predictive value of
73%, and an overall accuracy of 82%. Urinary IL-8 ana-
lyses (AUROC 0.79) had a sensitivity of 59%, specificity
of 97%, positive predictive value of 95%, negative predict-
ive value of 70%, and an accuracy of 78%. The difference
in AUROC between IL-8 and BTA was not significant
(0.79 vs. 0.75, p = 0.37). Urinary MMP-9 was also a rela-
tively accurate biomarker for BCa detection (AUROC:
0.75; 95% CI: 0.68-0.82, Figure 2). Urinary MMP-9
analyses revealed a sensitivity of 56%, specificity of 92%,
positive predictive value of 88%, negative predictive value
of 67%, and an accuracy of 74%. Urinary Syndecan was
not predictive for the presence of BCa (area under the
curve: 0.55; 95% CI: 0.45-0.65, Figure 2). Urinary Synde-
can monitoring resulted in a sensitivity of 70%, specifi-
city of 48%, positive predictive value of 58%, negative
predictive value of 61%, and an accuracy of 59%.
In multivariate logistic regression analysis, only
elevated urinary IL-8 (OR: 1.51; 95% CI: 1.16-1.97;
p= 0.002) was significantly associated with BCa. BTA,
MMP-9 and Syndecan levels were not significantly
associated with BCa in multivariate logistic regression
analysis (Table 2).
Discussion
Cancer of the urinary bladder is among the five most
common malignancies worldwide. Urothelial cell carcin-
omas constitute approximately 95% of all bladder cancer
Figure 1 Comparison of urine concentrations of interleukin 8 (IL-8), matrix metallopeptidase 9 (MMP-9), Syndecan and bladder tumor
antigen (BTA) between the cancer and non-cancer groups. Median levels are depicted by horizontal lines. Significance (p< 0.05) was assessed
by the Wilcoxon rank sum test.
Urquidi et al. BMC Urology 2012, 12:12 Page 4 of 7
http://www.biomedcentral.com/1471-2490/12/12cases, [11] and associated with tobacco exposure [12]. At
presentation, more than 80% of bladder tumors are non-
muscle invasive papillary tumors (Ta or T1), which
harbor a 5-year survival rate of approximately 94%, [13]
however, approximately 70% of patients with these
lesions develop tumor recurrence within two years of
initial diagnosis. The recurrence phenomenon of non-
muscle invasive BCa makes it one of the most prevalent
cancers world-wide (in America it is second only to
colorectal cancer) and is, therefore, a great burden to
healthcare systems [13]. Once BCa is detected and
treated, patients will routinely get frequent surveillance
cystoscopy to monitor for tumor recurrence [14]. If left
untreated these initially non-invasive tumors can
progress to muscle-invasive tumors which have signifi-
cantly reduced 5-year survival rate [15]. Thus, early
detection, ideally through non-invasive urine-based
analysis, remains one of the most urgent issues in BCa
research.In the current report, we describe the analysis of IL-8,
MMP-9 and Syndecan in a validation phase cohort of
127 subjects using ELISA assays. Urinary protein
concentrations of IL-8, MMP-9 and BTA were signifi-
cantly associated with BCa. IL-8 outperformed the other
experimental biomarkers (specificity 97% and positive
predictive value 95%). Multivariate logistic regression ana-
lysis highlighted only IL-8’s (OR: 1.51; 95% CI: 1.16-1.97)
association with BCa.
In performing studies discovering urinary biomarkers,
frozen (banked) urinary samples are critical. In the
current study, the cellular component of voided urine
was removed from the supernatant to prevent cellular
lysis, which may skew results upon thawing analyzing.
Upon reviewing available commercial assays to detect
BCa in urine samples, only BTA has been confirm on
frozen banked samples (see product insert) and thus
BTA-Trak served as one of our controls. BTA-Trak©
was the initial assay that was used to measure BTA in
Figure 2 (a) Receiver operating characteristic (ROC) curves for urinary IL-8, MMP-9, Syndecan and BTA. Based on the area under the ROC
curve (AUROC), Youden Index cutoff values that maximized the sum of sensitivity and specificity were determined for each biomarker (crossed
square on curve). Table provides performance values for each biomarker. PPV, positive predictive value. NPV, negative predictive value.
(b) Receiver operating characteristic (ROC) curves for the combination of IL-8, MMP-9 and Syndecan. Based on the area under the ROC curve
(AUROC), Youden Index cutoff values that maximized the sum of sensitivity and specificity were determined for combination of IL-8, MMP-9 and
Syndecan. Table provides performance values for each biomarker. PPV, positive predictive value. NPV, negative predictive value.
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[16]. Subsequently, BTA-Trak© was modified and incor-
porated into a point of care assay (BTA-stat©) which
received FDA approval in 1997 and has become a standard
tool in the non-invasive diagnosis ofBCa. BTA-Trak©,
median sensitivity is quoted as 71% (range: 60–83%) with
improved sensitivity in high-grade tumors. Median
specificity is 66% (range: 60–79%), significantly lower than
VUC [17].Table 2 Logistic regression analysis of biomarkers in
voided urine
Variable Coefficient Odds Ratio 95% C.I. p-value
IL-8 0.414 1.513 1.163 – 1.968 0.002
MMP-9 0.487 1.627 0.623 – 4.247 0.320
Syndecan -0.152 0.859 0.642 – 1.149 0.306
BTA-Trak 0.241 1.272 0.852 – 1.900 0.240Previous reports have implicated both IL-8 in bladder
tumor biology and for use as biomarkers of BCa. IL-8 is
an angiogenic factor associated with inflammation and
carcinogenesis, and previous reports have documented
elevated urinary protein levels of IL-8 in subjects with
urothelial cell carcinoma [18-20]. Studies have indicated
that elevated urinary levels are associated with increased
stage of disease, [18] disease recurrence [19] and lack of
efficacy of intravesical therapies, including bacillus
Calmette-Guérin and mitomycin C [21]. As an initial
diagnostic indicator, urinary IL-8 achieved a sensitivity of
59%, and a specificity of 90% in a study of 140 subjects
[18] and 50%/90% in a study of 79 subjects, [20] results
very much in line with our findings. In biological studies,
IL-8 has been shown to have mitogenic and angiogenic
properties, and high levels result in increased tumorigen-
icity, progression and metastasis in mouse models.
Inhibition of tumor growth in mouse xenograft models by
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of nuclear factor kappa-B [22].
Matrix metalloproteinase 9 (MMP-9) has been asso-
ciated with tumor cell invasion and metastasis in many
human cancers, including BCa. As a marker for BCa,
studies have reported that elevated urinary protein levels
of MMP-9 are associated with cancer. In a study of 188
subjects, high MMP-9 levels were significantly correlated
with large tumor size and poor malignancy grade, and
increasing levels were associated with poor overall sur-
vival [23]. Studies that measured urinary MMP-2 and
MMP-9 by both ELISA and zymography have suggested
that MMP-9 levels may be useful as an adjunct to
cytology, [24] or as a diagnostic with good sensitivity
(80%) [25]. Though we demonstrated that urinary
protein MMP-9 levels were significantly elevated in BCa
subjects by univariate analysis, this did not hold true in
logistic regression analysis, and the sensitivity in our
cohort was only 56%.
Similar to the study by Aaboe et al.,[26] we previously
identified Syndecan, a transmembrane heparin sulfate
proteoglycan, as a potential biomarker using gene
expression profiling [27]. We went on to confirm that it
was more highly expressed in urine samples from BCa
subjects via quantitative PCR of shed urothelia cells,
however, we were unable to confirm that Syndecan
protein was significantly elevated in the urines from BCa
subjects. This may be due to the fact that Syndecan is
membrane-bound and so is less likely to be present in
the soluble fraction of the urine, but a study has shown
elevated serum Syndecan levels to be an independent
prognostic marker for multiple myeloma [28].
In order to monitor whether experimental biomarkers
were associated with hematuria, urinary hemoglobin
levels were quantitated in each sample using ELISA. As
expected, hemoglobin was revealed to be significantly
elevated in the urines of subjects with BCa. Interestingly,
the levels of urinary BTA had the highest correlation
with urinary hemoglobin, raising the possibility that an
appreciable source of BTA is the blood routinely found
in BCa patients’ urine. This was previously suggested by
Oge et al.[29] We are currently investigating this possi-
bility in additional experiments. The accurate quantita-
tion of hematuria using a hemoglobin ELISA provides
valuable insight into the potential clinical utility of a bio-
marker prior to development of new assays designed to
detect BCa in voided urine samples [30].
We recognize that our study has several limitations. First,
processed, banked urines were analyzed. Urines were cen-
trifuged and separated into cellular pellet and supernatant
prior to storage at -800 C. It is feasible that freshly voided
urine samples may provide different results, and it is fresh
urine that would be the material used for point-of-care
assays. We are currently investigating the performance ofselected biomarkers in urines processed via a number of
different protocols. Second, it is uncertain how the protein
composition of the urine supernatant may change during
frozen storage. The number of freeze-thaw cycles was kept
to 1–2 by dividing the urine supernatant into multiple
small aliquots. Next, we are a tertiary care facility that is
preferentially referred high grade, higher stage disease,
which is reflected in our cohort. To confirm the robustness,
subsequent studies will assess more urines from subjects
with low-grade, low-stage disease in community urologic
practices. Subsequently, the sensitivity of VUC in our
cohort of predominantly high-grade (grade 3) disease (28%)
was lower than would be expected. This calls into question
the known inter-observer variability of interpreting VUC.
In subsequent studies, we will utilize two cytopathologists
to interpret these results. Lastly, our cohort was comprised
of two cohorts: active cancer or control cases with no active
cancer, no history of cancer, no urinary tract infection, no
urolithiasis, and no gross hematuria. This may account for
favorable detection levels with IL-8. Currently, we are
assessing our panel of validated biomarkers in a large
diverse cohort to further validate the robustness of this
diagnostic signature.Conclusions
We have demonstrated that urinary levels of IL-8 can be in-
dicative of BCa. The use of IL-8 in conjunction with other
validated biomarkers from our global profiling may prove
more efficacious than any single biomarker alone. Larger,
prospective studies are needed to determine the potential
utility of urinary IL-8 as a biomarker in the non-invasive
evaluation of patients who are at risk of harboring BCa.
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